Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews

joomla ecommerce template -- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

=================

CHAMPIONS TACKLING MS - AWARDS Dinner, Honoring Aaron Boster, MD and Jon e. Glaser, DDS - now open for registration. Visit www.events.msvn.org

Monday, September 12, 2016

Multiple Sclerosis: More Good News on Siponimod


                                                                  
  

Click here to receive MS news via e-mail

Sep 9, 2016

Patients with relapsing-remitting multiple sclerosis (RRMS) receiving siponimod treatment for 24 months had low disease activity and showed no new safety signals, according to an extension of the phase 2 BAF312 on MRI Lesion Given Once Daily (BOLD) study. The extension was conducted by Ludwig Kappos, MD, of the Neurologic Clinic and Proclinic, in the Department of Medicine at the University Hospital Basel in Switzerland, and colleagues, and was published in JAMA Neurology in July, 2016. - 

This study extension was dose-blinded and randomized, and the main outcomes included a safety assessment and efficacy measures. The researchers say, “Safety assessment included blood tests, documentation of adverse events at regular scheduled visits and Holter monitoring; key efficacy measures were annualized relapse rate and magnetic resonance imaging lesion activity.”   








MS Views and News
Providing educational information, resources and services for those affected by MS

No comments: